The future of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy.

摘要

Metastatic renal cell carcinoma (RCC) is observed in approximately 30% of patients at presentation and develops in 40% of patients with localized disease at presentation.1 Early-stage RCC can be cured by nephrect-omy, but metastatic RCC has a median survival time of only 12-15 months and a 5-year survival rate of less than 5%.2 One of the reasons for this poor outcome is the resistance of metastatic RCC to conventional chemotherapy.